Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07216859 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)

Study acronym: SCOUT Echo-AI
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Nov 1, 2027 → Nov 1, 2028
See other at-risk trials from Kaiser Permanente

Record History

  1. Primary and study completion pushed from Nov 1, 2027 to Nov 1, 2028
    • Start date: Jan 1, 2026 to Jan 1, 2028
    • Study sites: 4 to 6
    v3
  2. Start date: Nov 1, 2025 to Jan 1, 2026v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Kaiser Permanente
88 trials monitored
See 4 trials at risk
NASH / MASH
687 trials monitored
See 22 trials at risk
The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction associated steatotic liver disease (MASLD) and/or cirrhosis, in patients undergoing routine transthoracic echocardiograms (TTEs). The main question it aims to answer is to: 1. Evaluate notification responsiveness and rates of confirmatory testing for patients identified as high risk for having liver disease to determine whether optimized notifications increase timely confirmatory testing and treatment initiation versus standard of care assessment. 2. Compare time to diagnosis, treatment uptake, and clinical outcomes (hospitalizations, incident ASCVD, mortality) between cohorts identified as high risk by the AI algorithm and comparison groups to determine whether AI guided screening shortens time to diagnosis and increases appropriate treatment.
Trial Details
NCT Number NCT07216859
Lead Sponsor Kaiser Permanente
Collaborators: Stanford University, Massachusetts General Hospital, Cedars-Sinai Medical Center
Conditions
(from sponsor)		 MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
Related terms Fibrosis
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov